Update: Resminostat refocused cancer strategy begins
4SC’s recent €29m capital increase has provided vital funds to advance the epigenetic lead candidate resminostat. Focus is now on an EU Phase II trial in CTCL, rather than liver cancer (HCC). HCC would have been more costly and time-consuming compared with CTCL. Clinical data in 2016 in HCC and NSCLC from the Yakult collaboration will allow 4SC to revisit, with less risk, the prospects for resminostat in other cancers ex-Asia. Combination of resminostat with new immunotherapies is also being explored. Our valuation increases from €115m to €141m to reflect the cash increase and fresh development plans for resminostat in CTCL (EU).4SC is a biotechnology company that researches and develops drugs primarily for the treatment of cancer diseases. The Company has special expertise and clinical products in the field of epigenetics. 4SC's compounds aim to enable new therapeutic methods that offer improved efficacy and tolerability compared to the treatments available to date, both as monotherapy and in combination with other drugs. This approach is intended to enhance treatment benefits for affected patients, coupled with improvements to their life expectancy and quality of life. Adjusted for 1- for -5 stock split, April 2015Adjusted for 1- for -5 stock split, April 2015
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.